CD2 antigen targeting reduces intragraft expression of mRNA-encoding granzyme B and IL-10 and induces tolerance

Transplantation

Volumn 62, Issue 2, 1996, Pages 249-255

  Kapur, Sandip ^a   Khanna, Ashwani ^a   Sharma, Vijay K ^a   Li, Baogui ^a   Suthanthiran, Manikkam ^a  

^a Box 3 ^*

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; GRANZYME B; INTERLEUKIN 10; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RM2 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION REGULATION; GENE TARGETING; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD2; BASE SEQUENCE; EPITOPES; GENE EXPRESSION; GRAFT SURVIVAL; GRANZYMES; IMMUNE TOLERANCE; INTERLEUKIN-10; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED DBA; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERINE ENDOPEPTIDASES; TRANSCRIPTION, GENETIC;

EID: 0029898715     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199607270-00017     Document Type: Article

References (56)

1. Clevers H, Alarcon B, Wileman T, Terhorst C. The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol 1988; 6: 629.
2. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994; 76: 287.
3. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994; 76: 263.
4. Suthanthiran M. Signaling features of T cells: implications for the regulation of the anti-allograft response. Kidney Int 1993; 43: S-3.
5. Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol 1994; 6: 414.
6. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994; 15: 321.
7. Suthanthiran M. A novel model for the antigen-dependent activation of normal human t cells: Transmembrane signaling by crosslinkage of the CD3/T cell receptor-α/β complex with the cluster determinant 2 antigen. J Exp Med 1990; 171: 1965.
8. Selvaraj P, Plunkett ML, Dustin M, Sanders ME, Shaw S, Springer TA. The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature 1987; 326: 400.
9. Kato K, Koyanagi M, Okada H, et al. CD48 is a counter-receptor for mouse CD2 and is involved in T cell activation. J Exp Med 1989; 169: 1087.
10. Staunton DE, Fischer RC, LeBeau MM, et al. Blast-1 possesses a glycosyl-phosphatidylinositol (GPI) membrane anchor, is related to LFA-3 and OX-45, and maps to chromosome Iq21-23. J Exp Med 1989; 169: 1087.
11. Kato K, Tamura N, Okumura K, Yagita H. Identification of the T cell surface signal-transducing glycoprotein, sgp-60 as CD48, a counter-receptor for mouse CD2. Eur J Immunol 1993; 23: 1412.
12. 2+ and inositol triphosphate concentrations in murine T lymphocytes by glycosyl-phosphotidylinositol-anchored protein sgp-60. J Immunol 1993; 150: 3198.
13. Cabrero JG, Freeman GJ, Lane WS, Reiser H. Identification by protein sequencing and gene transfection, of sgp-60 as the murine homologue of CD48. Proc Natl Acad Sci USA 1993; 90: 3418.
14. Springer TA, Dustin ML, Kishimoto TK, Marlin SD. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Annu Rev Immunol 1987; 5: 223.
15. Altevogt P, Kohl U, Von Hoegen P, Lang E, Schirrmacher V. Antibody 12-15 cross-reacts with mouse Fey receptors and CD2: study of thymus expression, genetic polymorphism and biosynthesis of the CD2 protein. Eur J Immunol 1989; 19: 341.
16. Chavin KD, Qin L, Woodward JE, Lin J, Bromberg JS. Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance. Transplantation 1994; 57: 736.
17. Qin L, Chavin KD, Lin J, Yagita H, Bromberg JS. Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival. J Exp Med 1994; 170: 341.
18. Chavin KD, Qin L, Lin J, Kaplan AJ, Bromberg JS. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects. Transplantation 1993; 55: 901.
19. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardia allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992; 255: 1125.
20. Lenschow J, Zeng Y, Thistlethwaite R, et al. Long-term survival of xenographic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257: 789.
21. Turka LA, Linsley H, Lin W, et al. T cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102.
22. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801.
23. Yagita H, Nakamura T, Karasuyama JI, Okumura K. Monoclonal antibodies specific for murine CD2 reveal its presence on B as well as T cells. Proc Natl Acad Sci USA 1989; 86: 645.
24. Leo O, Foo M, Sachs DH, Samuelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 1987; 84: 1374.
25. Suthanthiran M. T-cell differentiation antigen cluster 2 (CD2) is a receptor for accessory cells and can generate and/or transduce accessory signals. Cell Immunol 1988; 112: 112.
26. Suthanthiran M. Oxidative mitogenesis: participation of CD2 antigen in the generation and/or transduction of obligatory accessory signals. Cell Immunol 1988; 114: 117.
27. O'Connell PJ, Pacheco-Silva A, Nickerson PW, et al. Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T cell activation transcripts. J Immunol 1993; 150: 1093.
28. Steiger J, Nickerson PW, Steurer W, Moscovitch-Lopatin M, Strom TB. IL-2 knockout recipient mice reject islet cell allografts. J Immunol 1995; 155: 489.
29. Lipman ML, Stevens AC, Strom TB. Heightened intragraft cytotoxic T lymphocyte gene expression in acutely rejecting renal allografts. J Immunol 1994; 152: 5120.
30. Xu G-P, Sharma VK, Li B, et al. Intragraft expression of IL-10 messenger RNA: a novel correlate of renal allograft rejection. Kidney Int 1995; 48: 1504.
31. Merville P, Lambert C, Durand I, et al. High frequency of IL-10-secreting CD4+ graft-infiltrating T lymphocytes in promptly rejected kidney allografts. Transplantation 1995; 59: 1113.
32. Sehajpal PK, Li B, Zanker B, et al. The molecular basis for the synergism between the CD3/αβ T cell receptor and the CD2 antigen-derived signals in promoting T cell proliferation. Transplantation 1991; 51: 468.
33. Sehajpal PK, Sharma VK, Ingulli E, Stenzel KH, Suthanthiran M. Synergism between the CD3 antigen and CD2 derived signals: exploration at the level of induction of DNA binding proteins and characterization of the inhibitory activity of cyclosporine. Transplantation 1993; 55: 1118.
34. Guckel B, Berek C, Lutz M, Altevogt P, Schirrmacher V, Kyewski BA. Anti-CD2 antibodies induce T cell unresponsiveness in vivo. J Exp Med 1991; 174: 957.
35. Chavin DK, Qin L, Lin J, Yagita H, Bromberg JS. Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies induce donor-specific tolerance in a cardiac transplant model. J Immunol 1993; 151: 7249.
36. Roark JH, Posselt AM, Campos L, et al. Prolongation of rat pancreatic islet allograft survival by anti-CD2 monoclonal antibody treatment. Transplantation 1992; 54: 1089.
37. Hirahara H, Tsuchida M, Watanabe T, et al. Long-term survival of cardiac allografts in rats treated before and after surgery with monoclonal antibody to CD2. Transplantation 1995; 59: 85.
38. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987; 165: 302.
39. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349.
40. Strom TB, Tilney NL, Carpenter CB, Busch GJ. Identity and cytotoxic capacity of cells infiltrating renal allografts. N Engl J Med 1975; 292: 1257.
41. Strom TB, Tilney NL, Paradyzs JM, Bancewicz J, Carpenter CB. Cellular components of allograft rejection: identity, specificity and cytotoxic function of cells infiltrating acutely rejecting allografts. J Immunol 1977; 118: 2020.
42. Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 1994; 76: 977.
43. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell: IV: Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1993; 170: 2081.
44. Moore KW, O'Garra A, deWaal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993; 11: 165.
45. Howard M, O'Garra A. Biological properties of interleukin 10. Immunol Today 1992; 13: 198.
46. Goldman M, Velu T. Interleukin-10 and its implications for immunopathology. In Grünfeld J-P, Bach JF, Kreiss H, Maxwell MH, eds. Advances in nephrology. St. Louis, MO: Mosby, 1995: 79.
47. Wogensen L, Huang X, Sarvetnick N. Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing IL-10 in the islets of Langerhans. J Exp Med 1993; 178: 175.
48. Lee M-S, Wogensen L, Shizuru J, Oldstone MBA, Sarvetnik N. Pancreatic islet production of murine IL-10 does not inhibit immune-mediated tissue destruction. J Clin Invest 1994; 93: 1332.
49. Wogensen L, Lee M-S, Sarvetnick N. Production of IL-10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice. J Exp Med 1994; 179: 1379.
50. Moritani M, Yoshimoto K, Tashiro K, et al. Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. Int Immunol 1994; 6: 1927.
51. Richter G, Krüger-Krasagakes S, Hein G, Hüls C, Schmitt E, Diamantstein T, Blankenstein T. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res 1993; 53: 4134.
52. Chen W-F, Zlotnik A. Interleukin 10: a novel cytotoxic T cell differentiation factor. J Immunol 1991; 147: 528.
53. Te Velde AA, de Waal Malefijt R, Huijbens RJF, de Vries JE, Figdor CG. IL-10 stimulates monocyte FcyR surface expression and cytotoxic activity: distinct regulation of antibody dependent cellular cytotoxicity by IFN-γ, IL-4 and IL-10. J Immunol 1992; 149: 4048.
54. Go NF, Castle BE, Barrett R, et al. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X-chromosome like immunodeficiency B cells. J Exp Med 1990; 172: 1625.
55. Yang G, Hellström KE, Mizuno MT, Chen L. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J Immunol 1995; 155: 3897.
56. Zheng XX, Steele AW, Nickerson PW, Steurer W, Steiger J, Strom TB. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol 1995; 154: 5590.